Aethlon Merges with North Immunology in $180M Deal to Advance Atopic Dermatitis Therapy — Aethlon Medical, Inc.

Event summary

Aethlon Medical to merge with North Immunology in an all-stock transaction, with the combined entity operating as North Immunology and trading under the ticker symbol NRTX.
The merger includes an oversubscribed $180 million private placement expected to fund operations into the second half of 2028.
North Immunology's lead program, NOR-101, is a bispecific antibody targeting IL-13 and IL-18 for atopic dermatitis, with Phase 1a study expected to begin in Q1 2027.
Aethlon stockholders will own approximately 4.75% of the combined company, with North Immunology stockholders owning the remaining 95.25%.
The transaction is expected to close in Q1 2027, subject to regulatory and shareholder approvals.

The big picture

The merger positions North Immunology to advance its lead candidate, NOR-101, a bispecific antibody targeting IL-13 and IL-18, which aims to address the unmet needs in atopic dermatitis treatment. The $180 million private placement underscores investor confidence in the combined entity's potential to deliver a best-in-disease therapeutic profile. This deal reflects the broader trend of biotech companies consolidating to accelerate the development of innovative therapies.

What we're watching

Clinical Development: The pace at which NOR-101 advances through Phase 1a, 1b, and 2b studies will determine its potential as a best-in-class treatment for atopic dermatitis.
Financial Runway: Whether the $180 million in funding will be sufficient to support the combined company's operations into the second half of 2028.
Market Positioning: How NOR-101's ability to target both type 2 and non-type 2 inflammation will position it against existing therapies in the atopic dermatitis market.